A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
- Status
- RECRUITING
- Phase
- PHASE1
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Rash & Diarrhea Prophylaxis With Capivasertib
- Status
- RECRUITING
- Phase
- PHASE2
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Single Dose of BL0175 in Postmenopausal Women
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2